Management of Glial Tumors: Viewpoint—Surgery and Intra-cavitary Radiopharmaceutical Therapy

  • Kaisorn L. Chaichana
  • Linda Chen
  • Salvador Manrique-Guzman
  • Lawrence Kleinberg
  • Alfredo Quinones-Hinojosa


Glial tumors are primary tumors of the central nervous system and can be divided into low and high-grade tumors. Even though there are no randomized control studies on extent of resection, there is a growing body of evidence supporting maximal, safe resection when surgery is pursued for patients with these tumors. The management of low-grade gliomas (World Health Organization grade II tumors) consists of maximal surgical resection without causing deficits for tumors that are growing or causing mass effect. Incidentally discovered, small low-grade gliomas can be considered for routine surveillance with frequent imaging. High-grade gliomas (World Health Organization grade III and IV tumors) should undergo maximal surgical resection while avoiding iatrogenic deficits. Despite maximal surgical resection, the majority of patients with both low and high-grade tumors will inevitably have recurrence and eventually die from progressive disease. The majority of this recurrence occurs in close proximity to the tumor margins. One type of adjuvant therapy that has been developed to increase radiation to the tumor margins while minimizing toxicity to surrounding normal brain parenchyma is intra-cavitary radiopharmaceutical therapy, also known as brachytherapy. This therapy involves placement of radioisotopes in the tumor bed either peri- or postoperatively and shows promise in that patients with both low and grade gliomas can undergo local radiation therapy, and therefore are not subjected to the neurocognitive problems associated with external brain radiation and the systemic toxicity of chemotherapy. However, clinical trials have yet to show a significant survival benefit for patients undergoing brachytherapy.


External Beam Radiation Therapy Total Resection Subtotal Resection 125I Seed Malignant Astrocytoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg. 2001;95(5):735–45.CrossRefPubMedGoogle Scholar
  2. 2.
    Piepmeier J, Baehring JM. Surgical resection for patients with benign primary brain tumors and low grade gliomas. J Neurooncol. 2004;69(1–3):55–65.CrossRefPubMedGoogle Scholar
  3. 3.
    Chaichana KL, Chaichana KK, Olivi A, Weingart JD, Bennett R, Brem H, et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. J Neurosurg. 2011;114(3):587–94. Clinical article.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Chaichana K, Parker S, Olivi A, Quinones-Hinojosa A. A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. J Neurosurg. 2010;112(5):997–1004 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].CrossRefPubMedGoogle Scholar
  5. 5.
    Chaichana KL, Garzon-Muvdi T, Parker S, Weingart JD, Olivi A, Bennett R, et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol. 2011;18(1):239–45 [Clinical Trial].PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Chaichana KL, Kosztowski T, Niranjan A, Olivi A, Weingart JD, Laterra J, et al. Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults. J Neurosurg. 2010;113(2):286–92 [Research Support, Non-U.S. Gov’t].CrossRefPubMedGoogle Scholar
  7. 7.
    Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quinones-Hinojosa A. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg. 2010;112(1):10–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Chaichana KL, McGirt MJ, Niranjan A, Olivi A, Burger PC, Quinones-Hinojosa A. Prognostic significance of contrast-enhancing low-grade gliomas in adults and a review of the literature. Neurol Res. 2009;31(9):931–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Chaichana KL, McGirt MJ, Woodworth GF, Datoo G, Tamargo RJ, Weingart J, et al. Persistent outpatient hyperglycemia is independently associated with survival, recurrence and malignant degeneration following surgery for hemispheric low grade gliomas. Neurol Res. 2010;32(4):442–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Chaichana KL, Zaidi H, Pendleton C, McGirt MJ, Grossman R, Weingart JD, et al. The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival. Neurol Res. 2011;33(7):759–64.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63(4):700–7; author reply 7–8.CrossRefPubMedGoogle Scholar
  12. 12.
    McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156–62.CrossRefPubMedGoogle Scholar
  13. 13.
    McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110(3):583–8 [Comparative Study].CrossRefPubMedGoogle Scholar
  14. 14.
    Liu BL, Cheng JX, Zhang X, Zhang W. Controversies concerning the application of brachytherapy in central nervous system tumors. J Cancer Res Clin Oncol. 2010;136(2):173–85 [Review].CrossRefPubMedGoogle Scholar
  15. 15.
    Ruge MI, Simon T, Suchorska B, Lehrke R, Hamisch C, Koerber F, et al. Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children: long-term outcome. J Clin Oncol. 2011;29(31):4151–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Chaichana KL, Halthore AN, Parker SL, Olivi A, Weingart JD, Brem H, et al. Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. J Neurosurg. 2011;114(3):604–12. Clinical article.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Chaichana KL, Parker SL, Mukherjee D, Cheng JS, Gokaslan ZL, McGirt MJ. Assessment of the extent of surgical resection as a predictor of survival in patients with primary osseous spinal neoplasms. Clin Neurosurg. 2011;58:117–21.CrossRefPubMedGoogle Scholar
  18. 18.
    Chaichana KL, Parker SL, Olivi A, Quinones-Hinojosa A. Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. J Neurosurg. 2009;111(2):282–92. Clinical article.CrossRefPubMedGoogle Scholar
  19. 19.
    McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery. 2009;65(3):463–9. discussion 9-70.CrossRefPubMedGoogle Scholar
  20. 20.
    Quinones-Hinojosa A, Chaichana K. The human subventricular zone: a source of new cells and a potential source of brain tumors. Exp Neurol. 2007;205(2):313–24.CrossRefPubMedGoogle Scholar
  21. 21.
    Tait MJ, Petrik V, Loosemore A, Bell BA, Papadopoulos MC. Survival of patients with glioblastoma multiforme has not improved between 1993 and 2004: analysis of 625 cases. Br J Neurosurg. 2007;21(5):496–500 [Randomized Controlled Trial Research Support, Non-U.S. Gov’t].CrossRefPubMedGoogle Scholar
  22. 22.
    Dandy WE. Removal of right cerebral hemisphere for certain tumors with hemiplegia. JAMA. 1928;90:823–5.CrossRefGoogle Scholar
  23. 23.
    Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Keles GE, Chang EF, Lamborn KR, Tihan T, Chang CJ, Chang SM, et al. Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg. 2006;105(1):34–40.CrossRefPubMedGoogle Scholar
  26. 26.
    Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99(3):467–73.CrossRefPubMedGoogle Scholar
  27. 27.
    Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, et al. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys. 2002;53(1):58–66.CrossRefPubMedGoogle Scholar
  28. 28.
    Tortosa A, Vinolas N, Villa S, Verger E, Gil JM, Brell M, et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer. 2003;97(4):1063–71.CrossRefPubMedGoogle Scholar
  29. 29.
    Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005;26(10):2466–74.PubMedGoogle Scholar
  30. 30.
    Grant R, Metcalfe SE. Biopsy versus resection for malignant glioma. Cochrane Database Syst Rev. 2005;2, CD002034.Google Scholar
  31. 31.
    Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol. 1999;42(3):227–31.CrossRefPubMedGoogle Scholar
  32. 32.
    Nazzaro JM, Neuwelt EA. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg. 1990;73(3):331–44.CrossRefPubMedGoogle Scholar
  33. 33.
    Quigley MR, Maroon JC. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery. 1991;29(3):385–8; discussion 8-9.CrossRefPubMedGoogle Scholar
  34. 34.
    Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753–64; discussion 264-6.CrossRefPubMedGoogle Scholar
  35. 35.
    Low-Grade Glioma Guidelines Team in association with the Guidelines and Outcomes Committee of the American Association of Neurological Surgeons. Practice parameters in adults with suspected or known supratentorial nonoptic pathway low-grade glioma. Neurosurg Focus. 1998;4(6):e10.CrossRefGoogle Scholar
  36. 36.
    Philippon JH, Clemenceau SH, Fauchon FH, Foncin JF. Supratentorial low-grade astrocytomas in adults. Neurosurgery. 1993;32(4):554–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Rajan B, Pickuth D, Ashley S, Traish D, Monro P, Elyan S, et al. The management of histologically unverified presumed cerebral gliomas with radiotherapy. Int J Radiat Oncol Biol Phys. 1994;28(2):405–13.CrossRefPubMedGoogle Scholar
  38. 38.
    van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry. 1998;64(5):581–7.PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Soffietti R, Chio A, Giordana MT, Vasario E, Schiffer D. Prognostic factors in well-differentiated cerebral astrocytomas in the adult. Neurosurgery. 1989;24(5):686–92.CrossRefPubMedGoogle Scholar
  40. 40.
    Pouratian N, Schiff D. Management of low-grade glioma. Curr Neurol Neurosci Rep. 2010;10(3):224–31 [Review].PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Wisoff JH, Sanford RA, Heier LA, Sposto R, Burger PC, Yates AJ, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s Oncology Group. Neurosurgery. 2011;68(6):1548–54. [Clinical Trial Multicenter Study Research Support, N.I.H., Extramural]; discussion 54-5.CrossRefPubMedGoogle Scholar
  42. 42.
    Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8):1338–45.CrossRefPubMedGoogle Scholar
  43. 43.
    Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg. 2011;115(5):948–65 [Review].CrossRefPubMedGoogle Scholar
  44. 44.
    Jung TY, Jung S, Moon JH, Kim IY, Moon KS, Jang WY. Early prognostic factors related to progression and malignant transformation of low-grade gliomas. Clin Neurol Neurosurg. 2011;113(9):752–7 [Randomized Controlled Trial].CrossRefPubMedGoogle Scholar
  45. 45.
    Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann Neurol. 1992;31(4):431–6.CrossRefPubMedGoogle Scholar
  46. 46.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96 [Clinical Trial Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.].CrossRefPubMedGoogle Scholar
  47. 47.
    House MG, Gonen M, Jarnagin WR, D’Angelica M, Dematteo RP, Fong Y, et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg. 2007;11(11):1549–55.CrossRefPubMedGoogle Scholar
  48. 48.
    Kreth FW, Thon N, Siefert A, Tonn JC. The place of interstitial brachytherapy and radiosurgery for low-grade gliomas. Adv Tech Stand Neurosurg. 2010;35:183–212 [Review].PubMedGoogle Scholar
  49. 49.
    Schwarz SB, Thon N, Nikolajek K, Niyazi M, Tonn JC, Belka C, et al. Iodine-125 brachytherapy for brain tumours—a review. Radiat Oncol. 2012;7:30 [Review].PubMedCentralCrossRefPubMedGoogle Scholar
  50. 50.
    Jalali R, Mallick I, Dutta D, Goswami S, Gupta T, Munshi A, et al. Factors influencing neurocognitive outcomes in young patients with benign and low-grade brain tumors treated with stereotactic conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77(4):974–9 [Research Support, Non-U.S. Gov’t].CrossRefPubMedGoogle Scholar
  51. 51.
    Korinthenberg R, Neuburger D, Trippel M, Ostertag C, Nikkhah G. Long-term results of brachytherapy with temporary iodine-125 seeds in children with low-grade gliomas. Int J Radiat Oncol Biol Phys. 2011;79(4):1131–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Voges J, Sturm V, Berthold F, Pastyr O, Schlegel W, Lorenz WJ. Interstitial irradiation of cerebral gliomas in childhood by permanently implanted 125-iodine–preliminary results. Klin Padiatr. 1990;202(4):270–4.CrossRefPubMedGoogle Scholar
  53. 53.
    Ostertag CB, Kreth FW. Iodine-125 interstitial irradiation for cerebral gliomas. Acta Neurochir (Wien). 1992;119(1–4):53–61.CrossRefGoogle Scholar
  54. 54.
    Voges J, Sturm VV. Interstitial irradiation with stereotactically implanted I-125 seeds for the treatment of cerebral glioma. Crit Rev Neurosurg. 1999;9(4):223–33.CrossRefPubMedGoogle Scholar
  55. 55.
    Voges J, Treuer H, Schlegel W, Pastyr O, Sturm V. Interstitial irradiation of cerebral gliomas with stereotactically implanted iodine-125 seeds. Acta Neurochir Suppl (Wien). 1993;58:108–11.Google Scholar
  56. 56.
    Kreth FW, Faist M, Grau S, Ostertag CB. Interstitial 125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adults: long-term results and prognostic factors. Cancer. 2006;106(6):1372–81.CrossRefPubMedGoogle Scholar
  57. 57.
    Bernstein M, Laperriere N, Glen J, Leung P, Thomason C, Landon AE. Brachytherapy for recurrent malignant astrocytoma. Int J Radiat Oncol Biol Phys. 1994;30(5):1213–7 [Clinical Trial].CrossRefPubMedGoogle Scholar
  58. 58.
    Laperriere NJ, Leung PM, McKenzie S, Milosevic M, Wong S, Glen J, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys. 1998;41(5):1005–11 [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov’t].CrossRefPubMedGoogle Scholar
  59. 59.
    Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery. 2002;51(2):343–55. [Clinical Trial Comparative Study Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S.]; discussion 55–7.PubMedGoogle Scholar
  60. 60.
    Ostertag CB. Brachytherapy–interstitial implant radiosurgery. Acta Neurochir Suppl (Wien). 1993;58:79–84 [Research Support, Non-U.S. Gov’t].Google Scholar
  61. 61.
    De Benedictis A, Moritz-Gasser S, Duffau H. Awake mapping optimizes the extent of resection for low-grade gliomas in eloquent areas. Neurosurgery. 2010;66(6):1074–84; discussion 84.CrossRefPubMedGoogle Scholar
  62. 62.
    Suchorska B, Ruge M, Treuer H, Sturm V, Voges J. Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection. Neuro Oncol. 2011;13(10):1133–42 [Clinical Trial].PubMedCentralCrossRefPubMedGoogle Scholar
  63. 63.
    Schupak K, Malkin M, Anderson L, Arbit E, Lindsley K, Leibel S. The relationship between the technical accuracy of stereotactic interstitial implantation for high grade gliomas and the pattern of tumor recurrence. Int J Radiat Oncol Biol Phys. 1995;32(4):1167–76.CrossRefPubMedGoogle Scholar
  64. 64.
    Gabayan AJ, Green SB, Sanan A, Jenrette J, Schultz C, Papagikos M, et al. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery. 2006;58(4):701–9. [Comparative Study]; discussion 9.CrossRefPubMedGoogle Scholar
  65. 65.
    Gobitti C, Borsatti E, Arcicasa M, Roncadin M, Franchin G, Minatel E, et al. Treatment of recurrent high-grade gliomas with GliaSite brachytherapy: a prospective mono-institutional Italian experience. Tumori. 2011;97(5):614–9 [Clinical Trial].PubMedGoogle Scholar
  66. 66.
    Welsh J, Sanan A, Gabayan AJ, Green SB, Lustig R, Burri S, et al. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Int J Radiat Oncol Biol Phys. 2007;68(1):159–65 [Evaluation Studies Multicenter Study].CrossRefPubMedGoogle Scholar
  67. 67.
    Chino K, Silvain D, Grace A, Stubbs J, Stea B. Feasibility and safety of outpatient brachytherapy in 37 patients with brain tumors using the GliaSite Radiation Therapy System. Med Phys. 2008;35(7):3383–8.CrossRefPubMedGoogle Scholar
  68. 68.
    Wu JS, Zhou LF, Tang WJ, Mao Y, Hu J, Song YY, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery. 2007;61(5):935–48. [Randomized Controlled Trial Research Support, Non-U.S. Gov't]; discussion 48-9.CrossRefPubMedGoogle Scholar
  69. 69.
    Schumacher M. Long-term results of brachytherapy with temporary iodine-125 seeds in children with low-grade gliomas. Int J Radiat Oncol Biol Phys. 2011;80(5):1604. [Comment Letter]; author reply.CrossRefPubMedGoogle Scholar
  70. 70.
    Schnell O, Scholler K, Ruge M, Siefert A, Tonn JC, Kreth FW. Surgical resection plus stereotactic 125I brachytherapy in adult patients with eloquently located supratentorial WHO grade II glioma - feasibility and outcome of a combined local treatment concept. J Neurol. 2008;255(10):1495–502.CrossRefPubMedGoogle Scholar
  71. 71.
    Kreth FW, Faist M, Rossner R, Birg W, Volk B, Ostertag CB. The risk of interstitial radiotherapy of low-grade gliomas. Radiother Oncol. 1997;43(3):253–60 [Clinical Trial Controlled Clinical Trial].CrossRefPubMedGoogle Scholar
  72. 72.
    Fabrini MG, Perrone F, De Franco L, Pasqualetti F, Grespi S, Vannozzi R, et al. Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas. Strahlenther Onkol. 2009;185(8):524–9.CrossRefPubMedGoogle Scholar
  73. 73.
    Gutin PH, Prados MD, Phillips TL, Wara WM, Larson DA, Leibel SA, et al. External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys. 1991;21(3):601–6 [Clinical Trial Multicenter Study Research Support, U.S. Gov’t, P.H.S.].CrossRefPubMedGoogle Scholar
  74. 74.
    Wen PY, Alexander 3rd E, Black PM, Fine HA, Riese N, Levin JM, et al. Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer. 1994;73(12):3029–36 [Clinical Trial Research Support, U.S. Gov’t, P.H.S.].CrossRefPubMedGoogle Scholar
  75. 75.
    Julow J, Kolumban Z, Viola A, Major T, Kolumban G. Prediction of volumetric change in the “triple ring” caused by glioma I-125 brachytherapy. Neuro Oncol. 2008;10(4):583–92 [Research Support, Non-U.S. Gov’t].PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Kaisorn L. Chaichana
    • 1
  • Linda Chen
    • 2
  • Salvador Manrique-Guzman
    • 1
  • Lawrence Kleinberg
    • 2
  • Alfredo Quinones-Hinojosa
    • 3
  1. 1.Department of NeurosurgeryJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of Radiation OncologyJohns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Department of Neurosurgery and OncologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations